PPARγ agonists inhibited MM cell survival byspecifically blocking the IL-6-dependent transactivation of STAT3 (signaltransducer and activator of transcription)-activated genes, including c-myc and mcl-1 [13]. The gene discussed is PPARG; the disease is Miyoshi myopathy.